Technical analyst PN Vijay has maintained 'buy' rating on Aurobindo Pharma Limited stock to attain a target of Rs 300.

According to analyst, the said target can be achieved within a period of 12 to 18 months.

The stock of the bank, on April 27, closed at Rs 195.20 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 19.31 and 10.19 respectively.

The share price has seen a 52-week high of Rs 275 and a low of Rs 157.25 on BSE.

Aurobindo Pharma has bagged green signal from US health regulator to make and market generic Divalproex Sodium Delayed-Release pills in the US market.

Divalproex Sodium Delayed-Release tablets are utilized for treating problems related to central nervous system.

Aurobindo Pharma, which has got final nod from USFDA, will shortly introduce the tabs in the potencies of 125mg, 250mg and 500mg in the US market.

As per IMS Health data, Divalproex Sodium Delayed-Release pills have a worldwide market size of around $144 million for the twelve months ending September 2010.

At present, the Hyderabad-based company has a total of 135 abbreviated new drug application (ANDA) authorizations from USFDA.